JEROME B. ZELDIS - 05 Apr 2022 Form 4 Insider Report for NexImmune, Inc. (NEXI)

Role
Executive VP of Research & Dev
Signature
/s/ Ilse Johnson, Attorney-in-fact
Issuer symbol
NEXI
Transactions as of
05 Apr 2022
Transactions value $
$0
Form type
4
Filing time
07 Apr 2022, 19:12:21 UTC
Previous filing
28 Mar 2022
Next filing
21 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NEXI Stock Option (Right to Buy) Award $0 +80.1K $0.00 80.1K 05 Apr 2022 Common Stock 80.1K $4.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on April 5, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Zeldis's continued service to the corporation on each vesting date.